Abbisko Cayman to Raise HK$517 Million via Discounted Share Placing for R&D Push

Abbisko Cayman Limited ( (HK:2256) ) has shared an update.

Abbisko Cayman Limited has launched a share placing under its general mandate, agreeing with a sole placing agent to place 42.9 million new shares to at least six institutional investors at HK$12.18 per share, an 8–9% discount to recent market prices. The new shares represent about 6.37% of the company’s issued share capital, and no placee is expected to become a substantial shareholder after completion.

The transaction is expected to raise gross proceeds of about HK$522.5 million and net proceeds of approximately HK$517.3 million, with roughly 90% earmarked for advancing R&D of oncology and non-oncology drug candidates, international multi-centre clinical trials and potential commercialization, and the remaining 10% for general corporate purposes. Completion remains subject to certain conditions, meaning the deal may not proceed, but if successful it will bolster Abbisko’s funding for its pipeline while modestly diluting existing shareholders and broadening its institutional investor base.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$27.10 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited is a biopharmaceutical company focused on the research and development of innovative oncology and non-oncology drug candidates. The company is listed on the Hong Kong Stock Exchange and targets global markets through international multi-centre clinical trials and potential commercialization activities.

Average Trading Volume: 1,809,597

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.21B

For detailed information about 2256 stock, go to TipRanks’ Stock Analysis page.